Dolores Hambardzumyan, PhD, MBA
- ASSOCIATE PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Neurosurgery
Research Topics:
Angiogenesis, Anti-Tumor Therapy, Bioinformatics, Blood-Brain Barrier, Brain, Brain Imaging, Cellular Immunity, Chemokines, Chemotaxis, Cytokines, Drug Resistance, Genomics, Knockout Mice, Microglia, Neurobiology, Neuroscience, Signal Transduction, Translational Research, Two-Photon ImagingDolores Hambardzumyan, PhD, MBA is a neuroscientist with a major focus on neuro-oncology. She conducts research on the brain tumor microenvironment and its impact on tumor response to therapy. Dr. Hambardzumyan has developed methods for immune profiling of brain tumors, including development of novel markers to distinguish and lineage-trace various populations of tumor-associated macrophages. She has demonstrated that genetic driver mutations can define the composition and function of the tumor microenvironment and can modify tumor response to therapy. She is particularly interested in developing novel therapeutic pathways for the treatment of glioblastoma in both children and adults. Dr. Hambardzumyan received a PhD in Biochemistry from the Buniatian Institute of Biochemistry at the National Academy of Sciences, Republic of Armenia, and an MBA from the Goizueta Business School at Emory University. She did postgraduate fellowships in cancer biology and radiation oncology at Memorial Sloan Kettering Cancer Center and in neuronal plasticity and transplantation at the French National Institute of Health and Research. She held previous academic appointments at Memorial Sloan Kettering Cancer Center, Cleveland Clinic, and Emory University.
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Neuroscience [NEU]Education
PhD, National Academy of Sciences, Armenia
MBA, Emory University Goizueta Business School
Diploma of Education, Executive Coaching, Emory University Goizueta Business School
Gliblastoma
Gliomas are the most frequently occurring primary brain tumor in children and adults. The most aggressive glioma subtype is the glioblastoma that remains amongst the deadliest form of human cancer. Glioblastomas are universally fatal, with a median survival of just over a year despite the most aggressive treatment regimens. Visit the Hambardzumyan Lab
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hambardzumyan did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.